AP NEWS

Critical Limb Ischemia - Pipeline Review, H2 2018: by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Critical Limb Ischemia - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Critical Limb Ischemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 18, 2, 1 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

1. Introduction

2. Overview

3. Therapeutics Development

4. Therapeutics Assessment

5. Companies Involved in Therapeutics Development

6. Drug Profiles

7. Dormant Projects

8. Discontinued Products

9. Product Development Milestones

Companies Featured

AnGes Inc apceth Biopharma GmbH Athersys Inc BiogenCell Ltd Caladrius Biosciences Inc Cynata Therapeutics Ltd Hemostemix Inc Histocell SL ID Pharma Co Ltd Integene International Holdings LLC Juventas Therapeutics Inc Kang Stem Biotech Co Ltd Kasiak Research Pvt Ltd Neurofx Inc Nissan Chemical Industries Ltd Pharmicell Co Ltd Pluristem Therapeutics Inc ReNeuron Group Plc Reven Pharmaceuticals Inc Rexgenero Ltd Symic Biomedical Inc TaiGen Biotechnology Co Ltd U.S. Stem Cell Inc VESSL Therapeutics Ltd ViroMed Co Ltd YiChang Humanwell Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rtq8hq/critical_limb?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005515/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 11:44 AM/DISC: 09/17/2018 11:44 AM

http://www.businesswire.com/news/home/20180917005515/en

AP RADIO
Update hourly